Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
CITYSCAPE
A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- NCT03563716 ↗
- Completed
- Genentech, Inc.
- Deep
We haven't built an HCP commentary report on CITYSCAPE (atezolizumab and tiragolumab in Non-small Cell Lung Cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on CITYSCAPE so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 11 | |
| YouTube | 7 | |
| Podcasts | 4 |
The trial
ClinicalTrials.gov- Official title
- A Phase II, Randomized, Blinded, Placebo-Controlled Study of Tiragolumab, An Anti-TIGIT Antibody, In Combination With Atezolizumab In Chemotherapy-Naïve Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Atezolizumab; Tiragolumab; Placebo
- Arms
- Placebo + Atezolizumab · Placebo comparator
- Tiragolumab + Atezolizumab · Experimental
- Enrollment
- 135
- Primary outcomes
- Objective Response Rate (ORR)
- Progression-free Survival (PFS)
- Sponsor
- Genentech, Inc.
- Start
- Aug 10, 2018
- Primary completion
- Jun 30, 2019
- Results posted
- Yes
- Registry record
- NCT03563716 · updated May 4, 2026
Publications
linked from the registry- Guan X, Hu R, Choi Y, Srivats S, Nabet BY, Silva J, McGinnis L, Hendricks R, Nutsch K, Banta KL, Duong E, Dunkle A, Chang PS, Han CJ, Mittman S, Molden N, Daggumati P, Connolly W, Johnson M, Abreu DR, Cho BC, Italiano A, Gil-Bazo I, Felip E, Mellman I, Mariathasan S, Shames DS, Meng R, Chiang EY, Johnston RJ, Patil NS. Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells. Nature. 2024 Mar;627(8004):646-655. doi: 10.1038/s41586-024-07121-9. Epub 2024 Feb 28. PubMed 38418879
- Cho BC, Abreu DR, Hussein M, Cobo M, Patel AJ, Secen N, Lee KH, Massuti B, Hiret S, Yang JCH, Barlesi F, Lee DH, Ares LP, Hsieh RW, Patil NS, Twomey P, Yang X, Meng R, Johnson ML. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study. Lancet Oncol. 2022 Jun;23(6):781-792. doi: 10.1016/S1470-2045(22)00226-1. Epub 2022 May 13. PubMed 35576957